Amphastar Pharmaceuticals, Inc.

DB:29A Stock Report

Market Cap: €1.7b

Amphastar Pharmaceuticals Past Earnings Performance

Past criteria checks 3/6

Amphastar Pharmaceuticals has been growing earnings at an average annual rate of 40.9%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 17.7% per year. Amphastar Pharmaceuticals's return on equity is 21.7%, and it has net margins of 21.8%.

Key information

40.9%

Earnings growth rate

40.4%

EPS growth rate

Pharmaceuticals Industry Growth7.3%
Revenue growth rate17.7%
Return on equity21.7%
Net Margin21.8%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Amphastar Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

DB:29A Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 247241589376
30 Jun 247131678872
31 Mar 246761558571
31 Dec 236441388074
30 Sep 236011357571
30 Jun 235411027272
31 Mar 23519936978
31 Dec 22499916775
30 Sep 22485776375
30 Jun 22477916267
31 Mar 22455816562
31 Dec 21438626761
30 Sep 21413366862
30 Jun 21384106769
31 Mar 2136826967
31 Dec 2035016367
30 Sep 2033776369
30 Jun 2033446270
31 Mar 20327525870
31 Dec 19322496369
30 Sep 19329526666
30 Jun 19324536759
31 Mar 1931626558
31 Dec 18295-65858
30 Sep 18265-75252
30 Jun 18248-95151
31 Mar 18242-45146
31 Dec 1724045144
30 Sep 1724305244
30 Jun 1725045144
31 Mar 1725294844
31 Dec 16255104742
30 Sep 16269214538
30 Jun 16268144339
31 Mar 1625404539
31 Dec 15252-34437
30 Sep 15230-134536
30 Jun 15226-154634
31 Mar 15221-104329
31 Dec 14210-114029
30 Sep 14209-63828
30 Jun 14209-13829
31 Mar 1422383630

Quality Earnings: 29A has high quality earnings.

Growing Profit Margin: 29A's current net profit margins (21.8%) are lower than last year (22.5%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 29A's earnings have grown significantly by 40.9% per year over the past 5 years.

Accelerating Growth: 29A's earnings growth over the past year (16.6%) is below its 5-year average (40.9% per year).

Earnings vs Industry: 29A earnings growth over the past year (16.6%) did not outperform the Pharmaceuticals industry 25.4%.

Return on Equity

High ROE: 29A's Return on Equity (21.7%) is considered high.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/10 13:17
End of Day Share Price 2025/01/10 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Amphastar Pharmaceuticals, Inc. is covered by 11 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Gary NachmanBMO Capital Markets Equity Research
Jason Matthew GerberryBofA Global Research
Timothy ChiangCapital One Securities, Inc.